INTRODUCTION
Schizophrenia is a severe mental disorder that affects the patient's perceptions, language, behavior, and thinking [1] . A prolonged course of therapy is required to treat this disease, which can impose a significant financial burden on the patient and their family [2, 3] . This is especially true in low and middle income countries that lack treatment facilities such as nursing homes and community rehabilitation centers [4, 5] .
Antipsychotic drugs account for much of the cost of schizophrenia treatment. The older, firstgeneration antipsychotic (FGA) drugs are efficacious in treating the positive symptoms of schizophrenia and are relatively inexpensive. However, these drugs can cause serious side effects, such as extrapyramidal symptoms and tardive dyskinesia, which can lead to irreversible damage and non-compliance by the patient [1, 6] . The newer, second-generation antipsychotic (SGA) drugs cause fewer side effects, are helpful in reducing the negative symptoms of schizophrenia, and are well tolerated by patients [7] but are costly compared to FGAs [8] . Schizophrenia may be treated with a single drug or a drug combination [9, 10] . FGAs and SGAs are commonly co-prescribed [10] , and this combination therapy has been shown to be effective in the treatment of acute psychotic symptoms.
Antipsychotic drugs may be administered orally or via long-acting antipsychotic injection (LAI).
LAIs have been shown to help prevent relapse and reduce hospitalizations [9, 11] and are particularly useful in the 50-60% of schizophrenic patients who are noncompliant [12, 13] . Combined oral administration of SGAs and LAI administration of FGAs has been shown to be particularly effective [13, 14] .
Variations in the prescribing pattern of antipsychotics exists among different countries due to factors including drug availability, efficacy, adverse effects, cost, and local prescription guidelines [15] . To date, no detailed study regarding antipsychotic use and its associated cost has been conducted in Pakistan. Therefore, this study will provide new insight into the antipsychotic prescribing practices in Pakistan and the costs associated with the use of antipsychotic drugs.
METHODS
This descriptive study was conducted in three major hospitals in the city of Peshawar, Khyber Pakhtun Khwa, Pakistan: the Sarhad Hospital for Psychiatric Diseases, Khyber Teaching Hospital, and Lady Reading Hospital. The study was approved by the ethical committee of Khyber Medical College, Peshawar (ref no. 19/RD/Cell/KMC) and was conducted in accordance with the 1964 Helsinki declaration. Informed consent to participate in the study was obtained from all patients, and patient data were coded for confidentiality [16] .
Using a convenience sampling method, 100 patients were recruited into this study between July 2014 and June 2015. This sample size, calculated using the World Health Organization sample size calculator, takes into account the high dropout rate expected to occur over the 1-year course of the study [17] . All patients included in the study were between 18 and 80 years old, had a diagnosis of schizophrenia (ICD-10 in the World Health Organization International Statistical Classification of Diseases and Related Health Problems classification system), and had at least one attendant. Patients with a co-morbid illness or with demographic data that were not credible were excluded from the study sample. As electronic patient medical records were not available in all of the selected hospitals, a questionnaire was developed to collect sociodemographic information and to record prescriptions of antipsychotics and other drugs. Patients and attendants were required to keep complete medical records during the 1-year course of the study and to complete the questionnaire at 4, 8 and 12 months, for a total of three assessments. Drug prices were obtained from Pharma-Guide Pakistan.
Data analysis
Patients were placed in three groups depending on the antipsychotic treatment regimen they received. Patients in Group I received antipsychotic monotherapy for the entire year. Patients in Group II received antipsychotic polytherapy. Patients in Group III switched from one treatment regimen to another during the course of the year.
The type of antipsychotic drug or drug combination prescribed for each patient was assessed. Within each group, the number of patients receiving a particular type of antipsychotic treatment was measured, and the percentage of patients receiving that treatment was calculated based on the total number of patients in that group. The annual antipsychotic cost was calculated as the mean cost per day multiplied by the number of days the antipsychotic was used. Statistical Package for Social Sciences (SPSS version 20, Chicago IL-USA) software was used calculates the mean annual antipsychotic prescription drug cost for all patients receiving a particular type of therapy using one-way ANOVA (post hoc analysis). For this study, a p-value of ≤ 0.05 was considered statistically significant.
RESULTS

Demographic and clinical variables
Twenty-eight patients failed to return for followup appointments and were excluded from the study, leaving 72 patients in the final study population. Demographic and clinical variables for patients in the final study population are shown in Table 1 . In the final population, 67.7 % of patients were male. The majority of patients (63.9 %) were young adults between 18 and 38 years of age. More than half of the patients (54.2 %) were married, and most (62.5 %) were educated. At the time of enrollment in the study, the mean duration of illness was 2.8 years, and the mean positive and negative syndrome scale score was 77.6. A slight majority of patients (40.3 %) received monotherapy. The remaining patients (34.7 %) received polytherapy. SGAs alone were prescribed to 68.1 % of patients, FGAs alone were prescribed to 6.9 % of patients, and a combination of SGAs and FGA was prescribed to 25 % of patients.
Drug prescription patterns and associated costs
The mean number of antipsychotics prescribed per patient was 1. Table 3 shows the drug prescription pattern and average annual drug cost for patients receiving antipsychotic polytherapy (Group II). This group represents 48.5 % of the final population. In this group, oral risperidone and oral olanzapine was the mostly prescribed drug combination (32 %), followed by oral risperidone and LAI fluphenazine (24 %). The mean cost of antipsychotic polytherapy was $103.20 USD (Rs. 10427). The most expensive polytherapy treatment, a combination of oral risperidone and oral olanzapine, cost $ 126.70 USD (Rs. 12797), or 39 % of the mean polytherapy cost. Post hoc LSD analysis using one-way ANOVA was used to assess whether various treatment regimens differed significantly in cost. 
DISCUSSION
Antipsychotic monotherapy is recommended by most antipsychotic treatment guidelines [9, 10] . In the present study, the percentage of patients receiving monotherapy was low compared with that in other countries [7, 10, 11] . The high incidence of polytherapy observed here may be due to the severity of symptoms; the patients from Sarhad Hospital for Psychiatrist Diseases who participated in this study were particularly unstable and may therefore have required more aggressive polytherapy treatment. Differences in study design may also account for the discrepancy in the number of patients receiving polytherapy. Tapp et al, for example, did not include drugs administered by LAI in the estimate of polytherapy treatment rates [10, 18] . According to National Institute for Clinical Excellence, SGAs should be used as first-line antipsychotics in the treatment of schizophrenia. Clozapine, olanzapine, and risperidone are the most effacious and well tolerated SGAs in most schizophrenic patients. In our study, the majority of patients were prescribed SGAs. These results are consistent with the results from similar studies conducted in Australia, Bahrain, Germany, and the United States, where most schizophrenic patients were treated with SGAs [7, 10, 11, 19, 20] .
Our study indicates that the use of antipsychotic polytherapy is similar between Pakistan and Finland.
Polytherapy is often used in the treatment of refractory schizophrenia. Polytherapy with FGAs and SGAs may be particularly effective because FGAs tend to act rapidly and may be able to quickly control psychotic symptoms until slower-acting SGAs become effective [10] . Polytherapy in which an SGA is administered orally and an FGA is administered by LAI is often recommended for patients who resist treatment [21] . However, the literature suggests that patient non-compliance is mainly due to the belief that side effects associated with LAI are worse than side effects associated with oral therapy [13] .
Polytherapy is also sometimes used early in treatment to manage the positive symptoms, and after these conditions are under control the patient is switched to SGA monotherapy. However a study conducted by Tapp et al [10] indicates that most psychiatrists found the FGA and SGA combination most effective and were therefore reluctant to switch from polytherapy to monotherapy. In this study, the rate of switching from one antipsychotic combination to another was 25 %. However, it is possible that some additional patients switched medications before the study began. The cost of SGAs in Pakistan is relatively low because most of the drugs are manufactured locally, although SGAs are still more expensive than FGAs [2, 4, 5] . Although SGA polytherapy, which typically combines an SGA and an FGA, can be considerably more expensive than monotherapy, the high cost of SGAs may be warranted, as it has been reported by Mauskopf and colleagues that treatment with SGAs reduces hospitalization and minimizes side effects, hence reducing overall medical cost and improving quality of life [22] .
Limitations of the Study
The study enrolled only a small number of patients. However, in a developing country, conducting a 1-year follow-up study is challenging.
CONCLUSION
The present study assessed the economic cost of antipsychotics used in the treatment of schizophrenia in Pakistan. SGAs, which are the most frequently prescribed antipsychotic drugs, are costly compared to FGAs. The results of the present study can be used to assess the pharmacoeconomics of antipsychotic prescription practices and to afford policymakers with information necessary for developing successful pharmacotherapeutic plans for the treatment of schizophrenia.
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